(Total Views: 424)
Posted On: 01/11/2021 2:53:51 PM
Post# of 36566
Either GNBT has to go up, or NGIO valuation has to go down.
It appears the market verdict is that GNBT has to go up. If that holds, I see a stock price of $2 to $5.
There is no reason why the NGIO valuation should go down. Their vaccine solution is more elegant and safe than the others.
The RNA solution produces 1791 antibodies that are non-neutralizing, and frankly with only a few months testing, no one knows what the long term effects will be of such a clumsy approach to a vaccine. As I understand it, there are only 9 neutralizing antibodies, and NGIO won't even use all of them.
At least on a theoretical level, if you are producing only the neutralizing antibodies, you should be much safer.
It appears the market verdict is that GNBT has to go up. If that holds, I see a stock price of $2 to $5.
There is no reason why the NGIO valuation should go down. Their vaccine solution is more elegant and safe than the others.
The RNA solution produces 1791 antibodies that are non-neutralizing, and frankly with only a few months testing, no one knows what the long term effects will be of such a clumsy approach to a vaccine. As I understand it, there are only 9 neutralizing antibodies, and NGIO won't even use all of them.
At least on a theoretical level, if you are producing only the neutralizing antibodies, you should be much safer.
(7)
(0)
